UNSPSC 51241132: Demecarium bromide

This classification denotes an anti-glaucoma agent and acetylcholinesterase inhibitor with the molecular formula C32H52N4O4.2Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61D5V4OKTP, chemically known as n,n-bis(3-trimethylammoniumphenoxycarbonyl)-n,n-dimethyldecamethylenediamine dibromide but more generally known as demecarium bromide, which bears US NIH Compound Identifier 5965. European Medicines Agency schedules Demecarium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06962MIG.

UNSPSC 51241132 Demecarium bromide (Commodity) covers pharmaceutical active ingredients and finished drugs supplied through state and local cooperative purchasing frameworks, with recent activity focused on generic multi-source pharmaceuticals and over-the-counter products distributed across participating government facilities. State and local buying under this code centers on bulk pharmaceutical procurement negotiated through wholesaler distribution networks, where issuing bodies contract with manufacturers to supply identified products at negotiated rates, with pricing formats including flat price, net price tiers, and WAC-minus structures. The primary issuing body pursuing this code is the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, which aggregates demand across multiple state and local government facilities including those in Oregon. MMCAP's cooperative-purchasing vehicle allows participating jurisdictions to leverage negotiated rates without conducting their own individual RFPs, reducing administrative burden for counties, cities, school districts, and other local entities.

Recent activity centers on Minnesota and Oregon through the MMCAP cooperative purchasing vehicle. The Minnesota Department of Administration issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products with a response deadline of March 26, 2026. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), maintain cGMP and DSCSA compliance, and carry comprehensive insurance including $5 million commercial general liability coverage. Awarded vendors receive contract terms of two years for new responders or alignment with existing agreement expirations through June 30, 2028 for incumbents, with contract effectiveness set for July 1, 2026. Evaluation weights price competitiveness at 75 percent, with remaining weight allocated to fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee applied to all contract purchases.